{"id":"NCT03724942","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type","officialTitle":"A Multicenter, Uncontrolled, Open-label Trial to Evaluate the Safety of Extended Treatment With Brexpiprazole (OPC-34712) to Patients With Agitation Associated With Dementia of the Alzheimer's Type","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-11-09","primaryCompletion":"2021-12-02","completion":"2022-01-05","firstPosted":"2018-10-30","resultsPosted":"2024-09-19","lastUpdate":"2024-09-19"},"enrollment":164,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Agitation Associated With Dementia of the Alzheimer's Type"],"interventions":[{"type":"DRUG","name":"Brexpiprazole","otherNames":["OPC-34712"]}],"arms":[{"label":"Brexpiprazole","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety of brexpiprazole 1 mg or 2 mg after a 14 week treatment regimen for agitation associated with dementia of the Alzheimer's type patients who completed in a double-blind trial, and to investigate the efficacy of brexpiprazole.","primaryOutcome":{"measure":"The Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"From baseline to week 14","effectByArm":[{"arm":"ROLLOVER BREX","deltaMin":90.2,"sd":null},{"arm":"ROLLOVER PLACEBO","deltaMin":90.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"55 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["40290781"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":102},"commonTop":["Somnolence","Insomnia","Fall","Sedation complication","Contusion"]}}